JP2007326873A - 肺動脈血管の血管平滑筋細胞の増殖を抑制する医薬を製造するための化合物の使用 - Google Patents
肺動脈血管の血管平滑筋細胞の増殖を抑制する医薬を製造するための化合物の使用 Download PDFInfo
- Publication number
- JP2007326873A JP2007326873A JP2007205383A JP2007205383A JP2007326873A JP 2007326873 A JP2007326873 A JP 2007326873A JP 2007205383 A JP2007205383 A JP 2007205383A JP 2007205383 A JP2007205383 A JP 2007205383A JP 2007326873 A JP2007326873 A JP 2007326873A
- Authority
- JP
- Japan
- Prior art keywords
- vip
- hypertension
- use according
- pulmonary
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 150000001875 compounds Chemical class 0.000 title claims description 34
- 210000001147 pulmonary artery Anatomy 0.000 title claims description 30
- 210000004509 vascular smooth muscle cell Anatomy 0.000 title claims description 16
- 230000035755 proliferation Effects 0.000 title claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 62
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 claims abstract description 48
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 claims abstract description 48
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims abstract description 45
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims abstract description 45
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims abstract description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 206010020772 Hypertension Diseases 0.000 claims abstract description 13
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims abstract description 13
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 41
- 229920001184 polypeptide Polymers 0.000 claims description 26
- 210000004072 lung Anatomy 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 12
- 230000004872 arterial blood pressure Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 230000008827 biological function Effects 0.000 claims description 5
- 230000035487 diastolic blood pressure Effects 0.000 claims description 5
- 230000035488 systolic blood pressure Effects 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 210000002565 arteriole Anatomy 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 abstract description 92
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 abstract description 92
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 abstract description 89
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 abstract description 43
- 230000004071 biological effect Effects 0.000 abstract description 11
- 210000004204 blood vessel Anatomy 0.000 abstract description 6
- 230000002685 pulmonary effect Effects 0.000 abstract description 6
- 230000003389 potentiating effect Effects 0.000 abstract description 3
- 230000004088 pulmonary circulation Effects 0.000 abstract description 3
- 230000001839 systemic circulation Effects 0.000 abstract description 3
- 230000010339 dilation Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 13
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 230000000004 hemodynamic effect Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 208000002815 pulmonary hypertension Diseases 0.000 description 8
- 102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 description 7
- 108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 description 7
- 101710090005 Vasoactive intestinal polypeptide receptor Proteins 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000006442 vascular tone Effects 0.000 description 7
- 101100080274 Mus musculus Nos3 gene Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 208000037849 arterial hypertension Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000036593 pulmonary vascular resistance Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000003071 vasodilator agent Substances 0.000 description 5
- 239000002023 wood Substances 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 4
- 108010084214 Peptide PHI Proteins 0.000 description 4
- 239000000132 Peptide PHI Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000000039 congener Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000001146 hypoxic effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000037905 systemic hypertension Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- 229940124549 vasodilator Drugs 0.000 description 4
- 208000007530 Essential hypertension Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- -1 Moody et al. Proteins 0.000 description 3
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 3
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 3
- 229960004166 diltiazem Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 229960001123 epoprostenol Drugs 0.000 description 3
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- SGAKZYXFPNRMLP-RMYDINGBSA-N 3b3-081716 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 SGAKZYXFPNRMLP-RMYDINGBSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 102400000686 Endothelin-1 Human genes 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 108020000631 PAC1 receptors Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000005737 Type I Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000013523 data management Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- 238000004868 gas analysis Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000960 hypophysis hormone Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- YLBIOQUUAYXLJJ-WZUUGAJWSA-N peptide histidine methionine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 YLBIOQUUAYXLJJ-WZUUGAJWSA-N 0.000 description 2
- 102000014187 peptide receptors Human genes 0.000 description 2
- 108010011903 peptide receptors Proteins 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002321 radial artery Anatomy 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- SOLIIYNRSAWTSQ-UHFFFAOYSA-N 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-n-pyridin-4-ylacetamide Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2C(C(=O)C(=O)NC=2C=CN=CC=2)=C1 SOLIIYNRSAWTSQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102100026278 Cysteine sulfinic acid decarboxylase Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- STGQSBKUYSPPIG-CIUDSAMLSA-N His-Ser-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 STGQSBKUYSPPIG-CIUDSAMLSA-N 0.000 description 1
- 101000962345 Homo sapiens NACHT, LRR and PYD domains-containing protein 12 Proteins 0.000 description 1
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100039240 NACHT, LRR and PYD domains-containing protein 12 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- RAGOJJCBGXARPO-XVSYOHENSA-N Phe-Thr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 RAGOJJCBGXARPO-XVSYOHENSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000014743 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Human genes 0.000 description 1
- 108010064032 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Proteins 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 101710137655 Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 description 1
- 102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 description 1
- 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 description 1
- 101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- FEJVSJIALLTFRP-LJQANCHMSA-N darusentan Chemical compound COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 FEJVSJIALLTFRP-LJQANCHMSA-N 0.000 description 1
- 229950008833 darusentan Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005120 human airway smooth muscle cell Anatomy 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 239000000601 hypothalamic hormone Substances 0.000 description 1
- 229940043650 hypothalamic hormone Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229960002240 iloprost Drugs 0.000 description 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PWDYHMBTPGXCSN-VCBMUGGBSA-N n,n'-bis[3,5-bis[(e)-n-(diaminomethylideneamino)-c-methylcarbonimidoyl]phenyl]decanediamide Chemical compound NC(N)=N/N=C(\C)C1=CC(C(=N/N=C(N)N)/C)=CC(NC(=O)CCCCCCCCC(=O)NC=2C=C(C=C(C=2)C(\C)=N\N=C(N)N)C(\C)=N\N=C(N)N)=C1 PWDYHMBTPGXCSN-VCBMUGGBSA-N 0.000 description 1
- IAYNHDZSSDUYHY-UHFFFAOYSA-N n-(2-acetyl-4,6-dimethylphenyl)-3-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxamide Chemical compound CC(=O)C1=CC(C)=CC(C)=C1NC(=O)C1=C(S(=O)(=O)NC2=C(C(C)=NO2)C)C=CS1 IAYNHDZSSDUYHY-UHFFFAOYSA-N 0.000 description 1
- YBWLTKFZAOSWSM-UHFFFAOYSA-N n-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=CN=CC=2)OC)=C1NS(=O)(=O)C1=CC=C(C)C=N1 YBWLTKFZAOSWSM-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000000720 neurosecretory effect Effects 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 108010064775 protein C activator peptide Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000008704 pulmonary vasodilation Effects 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 description 1
- 229960002578 sitaxentan Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229960005032 treprostinil Drugs 0.000 description 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
【解決手段】前記のペプチドは、肺及び細動脈高血圧症と関連して重要な役割を果たすと思われる少なくとも1種の特異的な高保存アミノ酸残基配列を含有する。これらの特異的な配列を有する公知の天然産ペプチドである“血管作動性腸管ペプチド(VIP)”及び“脳下垂体アデニル酸シクラーゼ活性化ポリペプチド(PACAP)”は、原発性肺高血圧症(PPH)、二次性肺高血圧症(SPH)、及び体循環の高血圧症を治療するために首尾よく使用できる有力な薬物である。
【選択図】なし
Description
原発性肺高血圧症(PPH)は、診断後3年以内に進行性の右心不全を引き起こす致命症である。最近、この疾患に関連した種々の病態生理学的変化、例えば血管狭窄、血管リモデリング(すなわち、肺動脈耐性血管の中膜及び内膜両方の増殖)、及び原位置の(in situ)血栓症が特定されている(例えば:D'Alonzo, G.E., Barst, R.J., Ayres, S.M. et al., Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med., 115, 343-349, 1-9-1991; Palevsky, H.I., Schloo, B.L., Pietra, G.G. et al., Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation, 80, 1207-1221. 1989; Rubin, L.J., Primary pulmonary hypertension. N. Engl. J. Med., 336, 111-117. 9-1-1997; Wagenvoort, C.A. and Wagenvoort, N., Primary pulmonary hypertension: a pathological study of the lung vessel in 156 clinically diagnosed cases. Circulation, 42, 1163-1184, 1970; Wood, P., Pulmonary hypertension with special reference to the vasoconstrictive factor. Br. Heart J., 20, 557-570, 1958)。血管及び内皮のホメオスターシスの欠陥は、プロスタサイクリン(PGI2)の合成低下、トロンボキサンの産生増大、酸化窒素の生成減少及びエンドセリン-1の合成増加から明らか
である(Giaid, A. and Saleh, D., Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med., 333, 214-221, 1995; Xue, C. and Johns, R.A., Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension [letter]. N. Engl. J. Med., 333, 1642-1644, 14-12-1995)。PPHにおいて肺動脈のVSMCの細胞内遊離カルシウム濃度が高められることが報告されている。
肺循環に匹敵して、体循環の内皮細胞は、血管平滑筋の緊張を調節し且つ本態性高血圧症の病態生理学に関わる弛緩因子と収縮因子とを放出する。内皮依存性の血管拡張は、主として酸化窒素によって調節されるが、しかしまた未確認の内皮誘導過分極因子及びプロスタサイクリンによっても調節される。内皮誘導収縮因子としては、エンドセリン-1、血管収縮薬プロスタノイド、アンギオテンシンII及びスーパーオキシドアニオンが挙げられる。生理学的条件下では、弛緩因子と収縮因子との均衡のとれた放出が存在する。この均衡は、心臓血管疾患、例えば高血圧症、アテローム性動脈硬化症、糖尿病及びその他の病気において変えることができ、それによって血管及び終末器の損傷のさらなる進行に寄与することができる。特に、酸化窒素の生体利用性の低下を招く内皮機能障害は、本態性高血圧症をもつ患者の内皮依存性の血管拡張を損ない、しかもアテローム性動脈硬化症の早期発生の決定因子でもあり得る。酸化窒素活性の低下の種々のメカニズムが、高血圧状態及び幾つかの心臓血管疾患において明らかにされており、内皮機能障害は血管の機能不全に先立って生じると思われる。
VIPは次のアミノ酸配列(N−末端からC−末端まで)からなるアミノ酸28個のペプチドである。
His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-GIn-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (配列番号1)
Said, S.I., VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells. Am. J. Physiol., 268, L1047-L1051, 1995)、毛髪成長活性、アポトーシス活性、著しい心臓血管副作用のない高められた持続性の気管支拡張活性を有することが明らかにされ、しかも喘息などの気管支痙攣、幾つかのケースの高血圧症、インポテンス、虚血症、ドライアイ及び精神障害、例えばアルツハイマー病に関連した疾患又は病気に対して有効である(例えば、国際出願公開第9106565号、欧州特許第0536741号、米国特許第3,880,826号、欧州特許第0204447号、欧州特許第0405242号、国際出願公開第9527496号、欧州特許第0463450号、欧州特許第0613904号、欧州特許第0663406号、国際出願公開第9735561号、欧州特許第0620008号公報参照)。
PACAPは、次のアミノ酸残基38個を含有する配列(N末端からC末端まで)からなるヒツジの視床下部から単離された神経ペプチドである:
His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-LysGln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-ArgTyr-Lys-Gln-Arg-Val-Lys-Asn-Lys (配列番号2)
His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu (配列番号3)
血管の緊張は、内皮、血管平滑筋細胞(VSMC)、外在性及び内在性神経のいずれかで局部的に産生される種々の血管作用性エフェクター物質の複雑なネットワークによって調節され、しかも血管の血流それ自体によって調節される。交感神経回路及び副交感神経回路の他に、末梢神経系由来の神経ペプチもまた血管緊張の調節において重要な役割を果たすと思われる。血管緊張の調節に最も重要な回路の一つは、内皮の酸化窒素合成酵素(ecnos、NOS III)による酸化窒素の産生である。
本発明の目的は、PPH、SPH、及び体循環の高血圧症の予防及び/又は治療に有用な公知化合物及び新規化合物の新規な使用を提供することにある。
Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu
を有し且つこのデカペプチド配列の近くにN末端方向にトリペプチド配列His-Ser-Asp及びPhe-Thr-Aspを有するポリペプチド又はペプチドが高血圧症の症状及び疾患を患う患者に投与した場合に肺動脈血管の血管平滑筋細胞の増殖を抑制する高い効果を示すことが知見された。この配列を有し且つ全体でアミノ酸残基を10〜38個、好ましくは10〜28個又は10〜23個有する化合物は、VIP又はPACAP(これらも前記の高保存配列を有する)と極めて似た生物学的機能又は同じ生物学的機能をもつ。本発明の別の結果は、VIP、PACUP及びその先端切断体(truncated form)、例えばPACAP−27もまた、ヒトの前記の病気の基礎となっている種々の細胞プロセスの阻害及び/又は調節によりPPH、SPH、及び体循環の高血圧症の予防及び治療用の高活性化合物であるということである。
(式中、X1〜X22は天然産アミノ酸残基である)
から選択されるペプチド又はポリペプチドが前記の治療機能及び効果を示すことができることが知見された。
・ 前記の特定のペプチド又はポリペプチド、好ましくはVIP、PACKAP及び先端切断PACKUPの生物学的機能を有する化合物を患者に投与することからなるヒトの肺動脈血管の平滑筋細胞(VSMC)の増殖を抑制するための使用
・ 前記の病気が原発性肺高血圧症(PPH)である前記の使用
・ 前記の病気が慢性閉塞性肺疾患(COPD)である前記の使用
・ 前記の病気が二次性肺高血圧症(SPH)である前記の使用
・ 前記の病気が細動脈高血圧症である前記の使用
・ 前記の細動脈高血圧症がPPHに関係したものである前記の使用
・ 前記の細動脈高血圧症がPPHに関係した心不全である前記の使用
・ 前記のペプチド及び/又はポリペプチドの投与後に肺動脈圧が10%よりも大きく、好ましくは20%よりも大きく、最も好ましくは30%よりも大きく低下する対応する使用
・ 前記の化合物の投与後に拡張期の血圧が5〜25%、好ましくは10〜20%低下し且つ収縮期の血圧が10〜30%、好ましくは10〜25%低下する対応する使用。
本発明の治療効果をもつ適当な化合物は、VIP又はPACAPの生物学的活性と同じ活性をもつ化合物であるが、低下した又は高められた生物学的活性をもつ化合物でもある。本発明の好ましい化合物は、同じか又は高められた生物学的活性をもつ。この群の範囲に入る化合物は全て、次の配列 Arg-Lys-Gin-Met-Ala-Val-Lys-Lys-Tyr-Leu を有する。
本発明で使用する化合物は、それを必要とする対象、例えばヒト患者に、それ自体で、あるいは適当な担体又は賦形剤と混合した医薬組成物として、病気の進行を少なくとも阻止するのに十分な用量で投与し得る。治療有効量は、単独で投与してもよいし、あるいはその他の医薬有効化合物、例えば他の血管拡張薬、例えばエポプロステロール、イロプロスト、ユニプロスト;カルシウムチャンネル遮断剤、例えばジルチアゼム;ホスホジエステラーゼアイソザイム阻害剤、例えばシルデナフィル、免疫抑制剤例えばグルココルチコステロイド類、例えばプレドニソロン、抗菌剤、例えば抗生物質、強心薬(inotropic agent)及び/又は血管拡張効果薬、例えばβ-アドレナリン作動性受容体 遮断剤及びアンギオテンシン受容体拮抗薬又はアンギオテンシン変換酵素阻害剤、例えばラミプリル、脂質低下及び抗増殖剤、例えばアトロバスタチン、エンドセリン受容体拮抗薬、例えばアルトラセンタン(Altrasentan)、シタックスセンタン(Sitaxsentan)、エンラセンタン、BMS 193884、ダルセンタン(Darusentan)、TBC 3711、BSP 208075、BSF 302146、SPP 301、あるいはその他の抗増殖性化合物、例えばD-24851、イマチニブメシレート、グアニルヒドラゾンCNI-1493と組み合わせて補助治療剤として投与してもよい。
VIPの血清濃度は、PPH患者、その他の患者又は健常対照の間で著しい相違を示す(図1)。VIP−Rの発現の免疫組織学的分析は、その発現と病気の状態との間の緊密な関係を明らかにする(図2a及び2b)。VIP−R mRNA蓄積は容易に検出できるPPHであるが、ほんの僅か低い水準のVIP−R mRNAの蓄積が健常対照において検出することができる(図3)。同様に、VIPに対する高められた受容体結合活性が、健常被験者に比べてPPH患者の肺耐性脈管から調製された肺動脈血管平滑筋細胞(PaVSMC)の一次培養物において認められる(図4a及び4b)。図8は、酸素正常状態及び低酸素の条件下での肺動脈のヒトの内皮細胞におけるecnos(NOS III)の発現に対するVIPの効果を表す。その状況ではecnosは常に低下する。薬理学的には、酸化窒素は、PaVSMCの細胞内遊離カルシウム濃度を低下させることによって血管拡張を誘発する。同様に、VIP作用の分子機構は、図9に例示されるようにVSMCにおける細胞内遊離カルシウム濃度の低下を明らかに伴う。また、VIPはPaVSMCの増殖を阻止する(図10)。ヒトの肺動脈の動脈輪に対するVIPの血管拡張効果を図6に示す。
重篤なPPHをもつ患者を、ジルチアゼム、フロセミド 及び抗凝血薬を用いて治療した。右心カテーテル挿入法(Swan-Ganz, Baxter, Irvine, CA, USA)を行って平均肺動脈圧(mpap)、心拍出量(CO)、平均動脈圧(MAP)、肺毛細管楔入圧(PCWP)、混合静脈血酸素飽和度(SVO2%)及び全身動脈酸素圧(PaO2%)を測定した。VIP(0.9%NaCl 3ml中100μg)を、3μmの粒度を使用するMicroDrop Master Jet (MPV、Truma、ドイツ)で15分間吸入させて前記の物質の肺胞沈殿(alveolar deposition)を得た。別法として、VIPをポータブルポンプ装置(CADD−1、Pharmacia-Upjohn、オーストリア国ヴィエンナ)によって20(ng/kg.b.w./min)をi.v.注射した。肺の血行動態及びガス交換を、VIPの吸入又はi.v.注射前又はその15分後に測定した。集中治療室で右心カテーテル挿入法を実施した。その患者をオンライン心電図で監視し、観血式血圧(invasive blood pressure)及び全身動脈酸素飽和度(SaO2%)(Hewlett Packard、ドイツ国ベーブリンゲン)を測定した。全ての血行動態及び酸素測定を、心拍出量コンピューター(Explorer、Baxter)及び圧力監視キット(Baxter, Irvine, CA, USA)を用いて行った。算出は患者データ管理装置(CareVue 9000、Hewlett Packard、ドイツ国ベーブリンゲン)で標準式に従って行った。血液ガス分析を橈骨動脈及び肺動脈から血液を採取することにより行った(自動血液ガス装置AVL−995−Hb、オーストリア国)。
VIPを用いて急性試験前及び後のPPH患者の血行動態パラメーターを図5及び6それぞれに要約する。ベースラン(VIPの吸入前)では、mPAPは63 mmHgであり、CIは3.6l・min−1であり、PVRは12 woodであり、PCWPは9 mmHgであり、PaO2は91%であり且つSvO2は61%であった。VIP 100μgの吸入添加は、肺の血行動態を向上し;ベースラインに比べてmPAPを49 mmHgに低下させ且つPVRを9 woodに低下させ、PaO2を93%に低下させ且つSvO2を63%に低下させた。
PPHを患っている患者において吸入VIPの用量を増やすと、用量に応じて平均肺動脈圧(mPAP)を低下させ、100μgで最大効果を示す。
PACAPの吸入量100μgは、PPHをもつ患者において時間経過に応じて平均肺動脈圧力(mPAP)を低下させる。
重いPPHをもつ患者を、ジルチアゼム、フロセミド及び抗凝血薬を用いて治療した。右心カテーテル法(Swan-Ganz, Baxter, Irvine, CA, USA)を行って平均肺動脈圧(mpap)、心拍出量(CO)、平均動脈圧(mAP)、肺毛細管楔入圧(PCWP)、混合静脈血酸素飽和度(SvO2%)及び全身動脈酸素圧(PaO2%)を測定した。PCAP(0.9%NaCl 3ml中100μg)を、3μmの粒度を使用するMicroDrop Master Jet (MPV, Truma, ドイツ国)により15分間吸入させて前記物質の肺胞沈殿を得た。肺の血行動態及びガス交換を、PACAPの吸入前又はその15分後に測定した。集中治療室で右心カテーテル法を実施した。この患者をオンライン心電図で監視し、観血式血圧及び全身動脈酸素飽和度(SaO2%)(Hewlett Packard、ドイツ国ベーブリンゲン)を測定した。全ての血行動態及び酸素測定を心拍出量コンピューター(Explorer, Baxter)及び圧力監視キット(Baxter, Irvine, CA, USA)を用いて行った。算出は患者データ管理装置(CareVue 9000、Hewlett Packard、ドイツ国ベーブリンゲン)で標準の式に従って行った。血液ガス分析を橈骨動脈及び肺動脈から血液を採取することにより行った(自動血液ガス装置AVL−995−Hb、オーストリア国)。
PACAPを用いて急性試験する前及びその後のPPH患者の血行動態パラメーターを図5bに要約する。ベースライン(PACAPの吸入前)では、mPAPは65 mmHgであり、CIは3.2 l・min−1であり、PVRは13 woodであり、PCWPは10 mmHgであり、PaO2は91%であり且つSvO2は59%であった。PACAP 100μgの吸入添加は、肺の血行動態を向上し;ベースラインと比べてmPAPを45 mmHgに低下させ且つPVRを8 woodに低下させ、PaO2を93%に低下させ且つSvO2を62%に低下させた。
慢性閉塞性肺疾患(COPD)を患い二次性肺高血圧症(SPH)(mPAP 32 mmHg)を有する患者を、吸入VIP(0.9%NaCl 3ml中200μg)に対する応答について試験した。VIPの吸入は、mPAPを32 mmHgから25 mmHgに低下させた。この効果は、心拍出量の4.1 1・min−1から4.8 l・min−1への増加に匹敵した。
重篤な本態性細動脈高血圧症を持つ患者を、ニフェジピン及びエナラプリルを用いて治療した。収縮期及び拡張期の全身動脈圧(SAP)を動脈内監視によって測定した。VIP(20 ng/kg/min)をポータブルポンプ装置(CADD−1、Pharmacia-Upjohn、オーストリア国ヴィエンナ)でi.v.注射した。VIPの血圧降下効果を図7に例示する。VIPの注射前は、収縮期血圧(SAP)は165 mmHgであり、拡張期血圧(DAP)は110 mmHgであった。VIPの施用は血圧の相当な低下をもたらし、収縮期血圧を145 mmHgに、拡張期血圧を90 mmHgに低下させた。
Claims (13)
- ヒトの肺及び/又は心臓組織の高血圧症の症状と直接又は間接的に相関関係がある病気又は疾患を患う患者を治療するためのヒト肺動脈血管の血管平滑筋細胞の増殖を抑制する医薬を製造するための化合物の使用であって、前記化合物が次の群:
(式中、X1〜X22は天然産アミノ酸残基である)
から選択されるペプチド 又はポリペプチドである前記医薬を製造するための化合物の使用。 - 前記医薬の単回投与量が20ng〜20μg/kg体重である請求項1に記載の使用。
- 前記ペプチド又はポリペプチドが同一の生物学的機能をもつ類縁体又は誘導体である請求項1〜2のいずれか1項に記載の使用。
- 前記ペプチド又はポリペプチドが安定化された形である請求項3に記載の使用。
- 前記の病気が原発性肺高血圧症(PPH)である請求項1〜4のいずれか1項に記載の使用。
- 前記の病気が慢性閉塞性肺疾患(COPD)である請求項1〜4のいずれか1項に記載の使用。
- 前記の慢性閉塞性肺疾患が二次性肺高血圧症(SPH)である請求項4に記載の使用。
- 前記の病気が細動脈高血圧症である請求項1〜4のいずれか1項に記載の使用。
- 前記の細動脈高血圧症がPPHに関連するものである請求項8に記載の使用。
- 前記の病気が PPHに関連した心不全である請求項1〜4のいずれか1項に記載の使用。
- 前記のペプチド又はポリペプチドのいずれかの投与後に肺動脈圧が10〜30%低下するものである請求項1〜10のいずれか1項に記載の使用。
- 前記のペプチド又はポリペプチドのいずれかの投与後に拡張期血圧が5〜25%低下し且つ収縮期血圧が10〜30%低下する請求項1〜10のいずれか1項に記載の使用。
- 前記のペプチド又はポリペプチドがVIP又はPACAP、これらの生物学的に活性な誘導体、先端切断体、類縁体又は融合タンパク質の生物学的機能をもつものであるか、あるいはこれらに機能的に類似しているものである請求項1に記載の使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00125935 | 2000-11-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002545716A Division JP2004514697A (ja) | 2000-11-28 | 2001-11-22 | 肺及び細動脈高血圧症治療用の血管作動性腸管ペプチドの生物学的活性をもつ化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007326873A true JP2007326873A (ja) | 2007-12-20 |
Family
ID=8170498
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002545716A Pending JP2004514697A (ja) | 2000-11-28 | 2001-11-22 | 肺及び細動脈高血圧症治療用の血管作動性腸管ペプチドの生物学的活性をもつ化合物 |
JP2007205383A Pending JP2007326873A (ja) | 2000-11-28 | 2007-08-07 | 肺動脈血管の血管平滑筋細胞の増殖を抑制する医薬を製造するための化合物の使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002545716A Pending JP2004514697A (ja) | 2000-11-28 | 2001-11-22 | 肺及び細動脈高血圧症治療用の血管作動性腸管ペプチドの生物学的活性をもつ化合物 |
Country Status (7)
Country | Link |
---|---|
US (3) | US20040063631A1 (ja) |
EP (2) | EP1792915A3 (ja) |
JP (2) | JP2004514697A (ja) |
CN (2) | CN1487952A (ja) |
AU (4) | AU2002220720B2 (ja) |
CA (1) | CA2428552A1 (ja) |
WO (1) | WO2002043746A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018016596A1 (ja) * | 2016-07-20 | 2018-01-25 | 国立大学法人東北大学 | PPARαアゴニストを含有する、肺高血圧症の予防又は治療剤 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2249701A (en) | 1999-11-12 | 2001-06-06 | David Bernstein | Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use |
WO2003061680A2 (en) * | 2002-01-26 | 2003-07-31 | Mondobiotech Laboratories Anstalt | Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease |
CA2488358A1 (en) * | 2002-06-10 | 2003-12-18 | Mondobiotech Laboratories Anstalt | Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis |
JP4942297B2 (ja) * | 2002-10-25 | 2012-05-30 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | 肺高血圧症の処置を目的としたn−{5−[4−(4−メチルピペラジノメチル)−ベンゾイルアミド]−2−メチルフェニル}−4−(3−ピリジル)−2−ピリジン−アミンの使用 |
ES2327640T3 (es) * | 2003-07-14 | 2009-11-02 | Mondobiotech Ag | Sustancias biologicamente activas a partir de un peptido intestinal vasoactivo para el tratamiento de afecciones pulmonares intersticiales. |
WO2005014030A1 (en) * | 2003-07-24 | 2005-02-17 | Lutz-Henning Block | Method for treating lung diseases associated with ventilation-perfusion mismatches |
CA2573439C (en) * | 2004-06-11 | 2014-12-09 | Vectus Biosystems Limited | Compositions and methods for treating myocardial fibrosis comprising vasoactive intestinal peptide |
US8702543B2 (en) * | 2005-01-20 | 2014-04-22 | Dayco IP Holding, LLC | Belt tensioner |
EP1896048A4 (en) * | 2005-05-06 | 2010-11-03 | Bayer Pharmaceuticals Corp | PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE |
AU2006275799B8 (en) * | 2005-07-28 | 2011-07-14 | Carbon Sink, Inc. | Removal of carbon dioxide from air |
CN101257947A (zh) * | 2005-09-12 | 2008-09-03 | 斯皮德尔药品公司 | 用于预防血管移植失败的吡啶磺酰胺基-嘧啶类 |
US8470778B2 (en) | 2005-12-09 | 2013-06-25 | Vectus Biosystems Limited | VIP fragments and methods of use |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8334257B2 (en) | 2005-12-20 | 2012-12-18 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
EP2152741B1 (en) | 2007-05-21 | 2011-09-21 | Res International Sarl | Peptides with improved properties having the biological activity of vasoactive intestinal peptide (vip) and their use for the treatment of lung diseases |
EP3412300A1 (en) | 2008-06-27 | 2018-12-12 | Duke University | Therapeutic agents comprising elastin-like peptides |
MX2011010341A (es) * | 2009-04-02 | 2012-01-27 | Vectus Biosystems Pty Ltd | Composiciones y metodos para el tratamiento de fibrosis aortica. |
EP2464370B1 (en) * | 2009-08-14 | 2017-03-29 | Phasebio Pharmaceuticals, Inc. | Modified vasoactive intestinal peptides |
CA2873553C (en) * | 2011-06-06 | 2020-01-28 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
GB201209745D0 (en) | 2012-05-31 | 2012-07-18 | Convatec Technologies Inc | Wound dressing |
ES2818824T3 (es) | 2014-05-08 | 2021-04-14 | Phasebio Pharmaceuticals Inc | Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística |
CA2976038A1 (en) | 2015-02-09 | 2016-08-18 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
MX2020007336A (es) * | 2018-01-09 | 2021-01-15 | Imagine Pharma Llc | Metodos y composiciones para modular la disfuncion de celulas endoteliales. |
CN110151973A (zh) * | 2019-04-25 | 2019-08-23 | 上海交通大学医学院附属瑞金医院 | 一种生物活性多肽pacap的应用 |
US20220202906A1 (en) * | 2019-05-07 | 2022-06-30 | Advita Lifescience Gmbh | Vasoactive intestinal peptide (vip) for use in the treatment of drug-induced pneumonitis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3898329A (en) * | 1971-09-17 | 1975-08-05 | Sami I Said | Vasoactive intestinal peptide, composition and method |
WO2000005260A1 (en) * | 1998-07-20 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Peptide analogues of pacap |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3880826A (en) * | 1971-09-17 | 1975-04-29 | Sami I Said | Vasoactive intestinal peptide |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4237046A (en) * | 1979-04-27 | 1980-12-02 | Miklos Bodanszky | Polypeptides and methods of preparation |
GB8427651D0 (en) | 1984-11-01 | 1984-12-05 | Beecham Group Plc | Compounds |
US4745100A (en) | 1985-05-14 | 1988-05-17 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion |
GB8525852D0 (en) | 1985-10-19 | 1985-11-20 | Beecham Group Plc | Compounds |
US4835252A (en) * | 1987-02-26 | 1989-05-30 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Vasoactive intestinal peptide analogs |
GB8729802D0 (en) | 1987-12-22 | 1988-02-03 | Beecham Group Plc | Novel compounds |
SE8705139D0 (sv) | 1987-12-23 | 1987-12-23 | Trion Forskning & Utveckling | Forfarande for framstellning av ett stort antal peptidanaloger och nya peptidanaloger |
IL87055A (en) * | 1988-07-08 | 1994-06-24 | Illana Gozes | Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5141924A (en) | 1989-06-30 | 1992-08-25 | Hoffmann-La Roche, Inc. | Synthetic vasoactive intestinal peptide analogs |
JPH04193896A (ja) | 1989-10-26 | 1992-07-13 | Meiji Seika Kaisha Ltd | 活性ペプチド |
ES2063406T3 (es) | 1990-06-26 | 1995-01-01 | Sanwa Kagaku Kenkyusho Co | Procedimiento para la preparacion de analogos de polipeptido intestinal vasoactivo. |
AU656230B2 (en) | 1991-10-11 | 1995-01-27 | F. Hoffmann-La Roche Ag | Cyclic vasoactive peptides |
JPH06220090A (ja) | 1993-01-22 | 1994-08-09 | Sanwa Kagaku Kenkyusho Co Ltd | ポリペプチド |
IL105061A (en) | 1993-03-16 | 2000-11-21 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of neurodegenerative diseases comprising VIP analogues and fragments thereof |
JPH07173197A (ja) | 1993-12-20 | 1995-07-11 | Sanwa Kagaku Kenkyusho Co Ltd | ポリペプチド修飾化合物及びその用途 |
JPH10502333A (ja) | 1994-04-07 | 1998-03-03 | プロティーンニックス カンパニー | バソアクティブ・インテスティナル・ポリペプチド |
CZ294779B6 (cs) | 1996-02-09 | 2005-03-16 | F.Hoffmann-La Roche Ag | Způsob přípravy Ac(1-31)-NH2 (SEQ ID NO:1) kopulací čtyř Fmoc chráněných peptidových VIP fragmentů a meziprodukty pro tento způsob |
US5688499A (en) * | 1996-03-13 | 1997-11-18 | Queen's University At Kingston | Antagonism of endothelin actions |
EP0914094A4 (en) | 1996-03-28 | 2000-03-01 | Univ Illinois | MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US6031002A (en) * | 1998-05-01 | 2000-02-29 | Michael Ebert | Method for enhancing female sexual response and a composition therefor |
DE19917713A1 (de) | 1999-04-09 | 2000-10-19 | Diagnostikforschung Inst | Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik |
US6630570B1 (en) * | 1999-04-09 | 2003-10-07 | Insitut für Diagnostikforschung GmbH | Short-chain peptide-dye conjugates as contrast media for optical diagnosis |
AU2249701A (en) * | 1999-11-12 | 2001-06-06 | David Bernstein | Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use |
-
2001
- 2001-11-22 CN CNA018196284A patent/CN1487952A/zh active Pending
- 2001-11-22 CA CA002428552A patent/CA2428552A1/en not_active Abandoned
- 2001-11-22 AU AU2002220720A patent/AU2002220720B2/en not_active Ceased
- 2001-11-22 EP EP07006174A patent/EP1792915A3/en not_active Withdrawn
- 2001-11-22 EP EP01998358A patent/EP1337557A2/en not_active Withdrawn
- 2001-11-22 US US10/416,822 patent/US20040063631A1/en not_active Abandoned
- 2001-11-22 CN CNA2007101437580A patent/CN101229363A/zh active Pending
- 2001-11-22 JP JP2002545716A patent/JP2004514697A/ja active Pending
- 2001-11-22 WO PCT/EP2001/013590 patent/WO2002043746A2/en active Application Filing
- 2001-11-22 AU AU2072002A patent/AU2072002A/xx active Pending
-
2006
- 2006-08-28 AU AU2006203749A patent/AU2006203749B2/en not_active Ceased
-
2007
- 2007-08-07 JP JP2007205383A patent/JP2007326873A/ja active Pending
- 2007-12-27 US US12/005,516 patent/US8153599B1/en active Active - Reinstated
- 2007-12-27 US US12/005,479 patent/US20080221041A1/en not_active Abandoned
-
2008
- 2008-08-25 AU AU2008207513A patent/AU2008207513A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3898329A (en) * | 1971-09-17 | 1975-08-05 | Sami I Said | Vasoactive intestinal peptide, composition and method |
WO2000005260A1 (en) * | 1998-07-20 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Peptide analogues of pacap |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018016596A1 (ja) * | 2016-07-20 | 2018-01-25 | 国立大学法人東北大学 | PPARαアゴニストを含有する、肺高血圧症の予防又は治療剤 |
Also Published As
Publication number | Publication date |
---|---|
US20080221041A1 (en) | 2008-09-11 |
AU2002220720B2 (en) | 2006-09-14 |
US8153599B1 (en) | 2012-04-10 |
JP2004514697A (ja) | 2004-05-20 |
AU2008207513A1 (en) | 2008-09-18 |
CN1487952A (zh) | 2004-04-07 |
EP1792915A3 (en) | 2008-03-12 |
EP1792915A2 (en) | 2007-06-06 |
AU2006203749A1 (en) | 2006-09-14 |
AU2072002A (en) | 2002-06-11 |
US20040063631A1 (en) | 2004-04-01 |
CA2428552A1 (en) | 2002-06-06 |
EP1337557A2 (en) | 2003-08-27 |
AU2006203749B2 (en) | 2009-06-04 |
CN101229363A (zh) | 2008-07-30 |
WO2002043746A2 (en) | 2002-06-06 |
WO2002043746A3 (en) | 2002-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8153599B1 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
AU2002220720A1 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
US7951778B2 (en) | Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis | |
CA1341060C (en) | Use of amylin agonists in the treatment of diabetes mellitus | |
JP6143740B2 (ja) | 持続性ペプチド類似体 | |
US20040242853A1 (en) | Glp-1 exendin-4 peptide analogs and uses thereof | |
EP2552470B1 (en) | Peptides for promoting angiogenesis and an use thereof | |
WO1994022467A1 (en) | Analogs of peptide yy and uses thereof | |
US20050118109A1 (en) | Method for treating lung diseases associated with ventilation-perfusion mismatches | |
JP2007513053A (ja) | 間質性肺感染症治療用の生物学的活性を有する血管作用性小腸ペプチドなる物質 | |
CA2320962C (en) | Novel mixed amylin activity compounds | |
US9249185B2 (en) | Peptides for promoting angiogenesis and an use thereof | |
CA2472270A1 (en) | Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease | |
US6936584B1 (en) | Mixed amylin activity compounds | |
KR20170069997A (ko) | 미리스토일화된 렙틴-관련된 펩티드 및 이들의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070905 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100908 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110111 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20110114 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110114 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110727 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111221 |